Cancer Vaccines

Positive Optivax Human Clinical Trial Results Announced

Published in Vaccine Weekly, March 10th, 1997

Vaxcel, Inc., Atlanta, Georgia, announced that a Phase I clinical trial has demonstrated both the safety and vaccine adjuvant activity of Optivax copolymers in humans.

A detailed presentation of the clinical trial results was given by the study's principal clinical investigators, Dr. Pierre L. Triozzi, the Ohio State University, at the joint meeting of the American Academy of Allergy, Asthma, and Immunology, the American Association of Immunologists, and the Clinical Immunology Society. The Phase I trial was conducted under contract with the Ohio State University Research Foundation.

"The copolymer vaccine adjuvant was well-tolerated and effective,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry